


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/495, 31/55		A1	(11) International Publication Number: WO 94/09780
			(43) International Publication Date: 11 May 1994 (11.05.94)
<p>(21) International Application Number: PCT/GB93/02197</p> <p>(22) International Filing Date: 25 October 1993 (25.10.93)</p> <p>(30) Priority data: 9223153.9 5 November 1992 (05.11.92) GB</p> <p>(71) Applicant (for all designated States except US): JOHN WYETH & BROTHER LIMITED [GB/GB]; Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0PH (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): CLIFFE, Ian, Anthony [GB/GB]; Priory View, One Pin Lane, Farnham Common, Bucks SL2 3RA (GB). FLETCHER, Allan [GB/GB]; 2 Grace Court, Farnham Road, Slough, Berkshire SL1 3GW (GB). WHITE, Alan, Chapman [GB/GB]; 7 Bulkely Close, Englefield Green, Surrey TW20 0NS (GB).</p>		<p>(74) Agents: BROWN, Keith, John, Symons et al.; Wyeth Laboratories, Huntercombe Lane South, Taplow, Maidenhead, Berkshire SL6 0PH (GB).</p> <p>(81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	
<p>(54) Title: USE OF PIPERAZINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS</p>			
<div style="text-align: center;">  <p style="text-align: right;">(I)</p> </div>			
<p>(57) Abstract</p> <p>Piperazine derivatives of formula (I) are useful in the treatment of cognitive disorders. In formula (I), X is a group of (IIa): $-(CH_2)_nCR^2R^3.CONR^4R^5$ or (IIb): $-A-NR^6COR^7$ where n, A, R, R^1, R^2, R^3, R^4, R^5, R^6 and R^7 have specified meanings.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Grèce	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

USE OF PIPERAZINE DERIVATIVES FOR THE TREATMENT OF COGNITIVE DISORDERS

This invention relates to the use of certain piperazine derivatives in the treatment of cognitive disorders

The piperazine derivatives are those of general formula



5 and the pharmaceutically acceptable acid addition salts thereof

In formula (I)

R is hydrogen or lower alkyl,

R¹ is an aryl or nitrogen containing heteroaryl radical,

10 and X is a group of formula



or



where

15 n is one of the integers 1 or 2,

R² is hydrogen or lower alkyl,

R³ is an aryl radical or an aryl(lower)alkyl radical,

R⁴ is hydrogen or lower alkyl,

R^5 is hydrogen, an alkyl group of 1 to 8 carbon atoms, cycloalkyl of 3 to 12 carbon atoms or cycloalkyl(lower)alkyl,


5 or R^4 and R^5 together with the nitrogen atom to which they are attached represent an azetidino, pyrrolidino, piperidino, hexahydroazepino, morpholino or piperazino ring which may be optionally substituted by lower alkyl, aryl or aryl(lower)alkyl,

10 A is an alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups,

R^6 is a mono or bicyclic heteroaryl radical

and R^7 is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, 15 aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula $-NR^8R^9$ [where R^9 is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R^{10} is hydrogen, lower alkyl, $-CO(lower)alkyl$, aryl, $COaryl$, aryl(lower)alkyl, cycloalkyl or cycloalkyl(lower)alkyl 20 or R^8 and R^9 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom] or a group of formula OR^{11} [where R^{11} is lower 25 alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl or heteroaryl-(lower)alkyl].

Preferred compounds of formula I are those of



or the pharmaceutically acceptable acid addition salts thereof (where n , R , R^1 , R^2 , R^3 , R^4 and R^5 are as defined above).

- 5 The term "lower" as used herein means that the radical referred to contains 1 to 6 carbon atoms. Preferably such radicals contain 1 to 4 carbon atoms. Examples of "lower alkyl" radicals are methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and isopentyl. Examples of cycloalkyl groups are cyclopentyl, 10 cyclohexyl and cycloheptyl. A preferred example is cyclohexyl. Cycloalkyl groups include bicyclic, tricyclic and tetracyclic groups, eg adamantyl. Preferably the cycloalkyl group contains 3 to 12 carbon atoms.
- 15 When used herein "aryl" means an aromatic radical having 6 to 12 carbon atoms (eg phenyl or naphthyl) which optionally may be substituted by one or more substituents. Preferred substituents are lower alkyl, lower alkoxy (eg methoxy, ethoxy, propoxy, butoxy), 20 halogen, halo(lower)alkyl (eg trifluoromethyl), nitro, nitrile, amido, (lower)alkoxycarbonyl, amino, (lower)alkylamino or di(lower)alkylamino substituents. Two substituents on the aromatic ring may be connected together to form another ring system.
- 25 When R^1 is an aryl radical it is preferably a phenyl radical containing a substituent in the ortho position. A preferred example of R^1 is o-(lower)alkoxyphenyl eg o-methoxyphenyl. R^1 can also be, for example a 1-naphthyl radical optionally substituted in the 2 or 7 30 positions by, for example, (lower)alkoxy.

Preferred examples of aryl(lower)alkyl are benzyl and phenethyl in which the phenyl rings may be substituted

by substituents as given above.

When used herein "nitrogen containing heteroaryl radical" means an aromatic ring containing one or more nitrogen atoms as heteroatoms (eg pyridinyl, pyrimidinyl or pyrazinyl) which may optionally be substituted by one or more lower alkyl, lower alkoxy, halogen, trifluoromethyl, amino, (lower)alkylamino or di(lower)alkylamino substituents. Preferably the heteroaryl radical is monocyclic.

When R^6 is a bicyclic heteroaryl radical both rings of the radical may contain hetero ring atoms or only one ring may contain a hetero atom or atoms. In the latter instance the radical R^6 is connected to the rest of the molecule of formula (I) via the ring containing the hetero atom(s).

Examples of the heteroaryl radical R^6 include monocyclic radicals containing one hetero atom, eg optionally substituted pyridyl (particularly 2-pyridyl), monocyclic radicals containing two hetero atoms, eg thiazolyl (particularly 2-thiazolyl) and bicyclic radicals containing one or two hetero atoms eg quinolinyl or isoquinolinyl (particularly 2-quinolinyl).

The piperazine derivatives of formula (I) and their method of preparation are disclosed, for example, in

GB 2230780A

GB 2230781A

GB 2248836A

and GB 2255337A

The compounds disclosed in GB 2230780A are described as

antidepressant and/or anxiolytic agents. The compounds disclosed in GB 2230781A, GB 2248836A and GB 2255337A are disclosed as 5-HT_{1A} antagonists useful for the treatment of CNS disorders such as anxiety, as
5 antidepressants, hypotensives and as agents for regulating the sleep/wake cycle, feeding behaviours and/or sexual function.

The preferred compounds of formula (I) are:

10 N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide and its (S)-enantiomer

2,3,4,5,6,7-hexahydro-1-[4-[1-[4-(2-methoxyphenyl)-piperazinyl]]-2-phenyl]butanoyl-1H-azepine

15 (-)-(R)-2,3,4,5,6,7-hexahydro-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine

N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide

and their pharmaceutically acceptable acid addition salts.

20 The present provides in one aspect, a method of treating cognitive disorders which comprises administering to a human in need thereof an effective amount of a compound of formula (I) as defined above or a pharmaceutically acceptable acid addition salt
25 thereof. In a second aspect the invention provides the use of a compound of formula (I) as defined above or a pharmaceutically acceptable acid addition salt thereof for the manufacture of a medicament for the treatment of cognitive disorders.

The compounds are useful in the treatment of cognitive disorders such as memory deficits and dementia states. Examples of such states occur, for example, in senile dementia (eg Alzheimer's disease), brain damage caused
5 by stroke and brain injuries, and age associated memory impairment.

In this specification the terms "treatment" and "treating" relate to the administration of the compounds to prevent the disorder as well as to treat
10 the disorder or to alleviate the symptoms of the disorder.

The efficacy of the compounds for treating cognitive disorders can be examined in two ways. First, the influence of compounds on learning and memory in normal
15 animals is examined by comparing the performance of compound-treated animals to vehicle treated control animals. Compounds that improve learning and memory are expected to enhance performance whereas compounds that interfere with learning and memory would be
20 predicted to impair performance in the learning and memory tasks. Second, in an attempt to model specific diseases, learning and memory deficits can be experimentally-induced and the ability of target substances to reverse the resulting cognitive deficits
25 examined. For example, in order induce cognitive deficits and to model the deficiency in central glutamatergic neurotransmission which occurs in Alzheimer's Disease, antagonists of glutamate receptors can be administered to animals which are then tested in
30 a suitable behavioural procedure (e.g. the radial arm maze). In this procedure the selective 5-HT_{1A} antagonist, (-)-(R)-2,3,4,5,6,7-hexahydro-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine, has been shown to reverse the cognitive

deficits induced by the glutamate receptor antagonist, MK-801. Animals were required to learn and remember in which parts of the apparatus they could locate food rewards. The administration of MK-801 (0.1 mg/kg i.p.) significantly increased the number of errors made by the animals, compared to vehicle-pretreated controls. At doses of 0.3 and 3.0 mg/kg s.c., the 5-HT_{1A} antagonist, (-)-(R)-2,3,4,5,6,7-hexahydro-1-[4-[4-(2-methoxyphenyl)-piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine, significantly reversed the cognitive deficit induced by MK-801.

The compounds may be used in treating cognitive disorders in their free base form or as acid addition salts.

Examples of acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric, acetic, formic, methanesulphonic, p-toluenesulphonic, oxalic and succinic acids.

The compounds of formula I contain one or more asymmetric carbon atoms, so that the compounds can exist in different stereoisomeric forms. The compounds can, for example, exist as racemates or optically active forms.

The compounds may be used for treating cognitive disorders in the form of pharmaceutical compositions which comprise a compound of formula I or a pharmaceutically acceptable acid addition salt thereof in association with a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical composition. In

such a composition, the carrier is generally a solid or liquid or a mixture of a solid or liquid.

5 Solid form compositions include powders, granules, tablets, capsules (eg hard and soft gelatine capsules), suppositories and pessaries. A solid carrier can be, for example, one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, fillers, glidants, compression
10 aides, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary compression properties in suitable
15 proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99%, eg from 0.03 to 99%, preferably 1 to 80% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate,
20 talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.

25 The term "composition" is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is surrounded by the carrier, which is thus in association with it. Similarly cachets are included.

30 Liquid form compositions include, for example, solutions, suspensions, emulsions, syrups, elixirs and pressurised compositions. The active ingredient, for example, can be dissolved or suspended in a

- pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilisers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, eg cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols, eg glycerol and glycols) and their derivatives, and oils (eg fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. When the compound is orally active it can be administered orally either in liquid or solid composition form.

Preferably the pharmaceutical composition is in unit dosage form, eg as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged composition, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquid. The unit dosage form can be, for example, a capsule or tablet itself,

or it can be the appropriate number of any such compositions in package form. The quantity of the active ingredient in unit dose of composition may be varied or adjusted from 0.5 mg or less to 750 mg or
5 more, according to the particular need and the activity of the active ingredient.

The following Examples illustrate the invention:

Example 1Preparation of Tablets

		<u>Amount per tablet mg</u>		
5	(-)-(R)-2,3,4,5,6,7-Hexahydro-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine	1	5	10
	Microcrystalline cellulose	49.25	47.25	44.75
10	Modified food corn starch	49.25	47.25	44.75
	Magnesium stearate	0.5	0.5	0.5

Tablets are prepared from bulk amounts of ingredients in the proportions given above.

15 All of the active compound, cellulose and a portion of the corn starch are mixed and granulated to 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 1, 5 and 10
20 mg of the active ingredient per tablet.


Example 2Preparation of powder filled capsules

		<u>Amount mg</u>	
5	N-tert.butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide	10	15
	Avicel	45	
	Lactose	153	
	Starch (1500 NF)	-	117
10	Sodium starch glycollate	-	6
	Magnesium stearate	2	2

15 The formulations are prepared by admixing the ingredients in the proportions given above and filling two-part hard gelatin capsules with the required amount of the resulting mixture to give capsules containing 10 or 15 mg of the active compound.

CLAIMS

1. The use of a piperazine derivative of general formula (I)




or a pharmaceutically acceptable acid addition salt thereof

where R is hydrogen or lower alkyl,

R¹ is an aryl or nitrogen containing heteroaryl radical,

and X is a group of formula



or



where

n is one of the integers 1 or 2,

R² is hydrogen or lower alkyl,

R³ is an aryl radical or an aryl(lower)alkyl radical,

R⁴ is hydrogen or lower alkyl,

R⁵ is hydrogen, an alkyl group of 1 to 8 carbon atoms, cycloalkyl of 3 to 12 carbon atoms or cycloalkyl(lower)alkyl,

or R^4 and R^5 together with the nitrogen atom to which they are attached represent an azetidino, pyrrolidino, piperidino, hexahydroazepino, morpholino or piperazino ring which may be optionally substituted by lower alkyl, aryl or aryl(lower)alkyl,


A is an alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups,

R^6 is a mono or bicyclic heteroaryl radical

and R^7 is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula $-NR^8R^9$ [where R^9 is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R^{10} is hydrogen, lower alkyl, $-CO(lower)alkyl$, aryl, $COaryl$, aryl(lower)alkyl, cycloalkyl or cycloalkyl(lower)alkyl or R^8 and R^9 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom] or a group of formula OR^{11} [where R^{11} is lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl or heteroaryl-(lower)alkyl]

for the manufacture of a medicament for the treatment of cognitive disorders.

2. The use as claimed in claim 1 wherein the compound of general formula (I) has the formula



where n , R , R^1 , R^2 , R^3 , R^4 and R^5 are as defined in claim 1.

3. The use as claimed in claim 1 wherein the compound of formula (I) is


N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide or its (S)-enantiomer or

2,3,4,5,6,7-hexahydro-1-[4-[1-[4-(2-methoxyphenyl)-piperazinyl]]-2-phenyl]butanoyl-1H-azepine or

(-)-(R)-2,3,4,5,6,7-hexahydro-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine or

N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide.

4. A method of treating cognitive disorders which comprises administering to a human in need thereof an effective amount of a piperazine derivative of general formula (I)



or a pharmaceutically acceptable acid addition salt thereof

where R is hydrogen or lower alkyl,

R^1 is an aryl or nitrogen containing heteroaryl radical,

and X is a group of formula



or



where

n is one of the integers 1 or 2,

R^2 is hydrogen or lower alkyl,

R^3 is an aryl radical or an aryl(lower)alkyl radical,

R^4 is hydrogen or lower alkyl,

R^5 is hydrogen, an alkyl group of 1 to 8 carbon atoms, cycloalkyl of 3 to 12 carbon atoms or cycloalkyl(lower)alkyl,

or R^4 and R^5 together with the nitrogen atom to which they are attached represent an azetidino, pyrrolidino, piperidino, hexahydroazepino, morpholino or piperazino ring which may be optionally substituted by lower alkyl, aryl or aryl(lower)alkyl,


A is an alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower alkyl groups,

R^6 is a mono or bicyclic heteroaryl radical

and R^7 is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula $-\text{NR}^8 \text{R}^9$ [where R^9 is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R^{10} is hydrogen,

lower alkyl, -CO(lower)alkyl, aryl, COaryl, aryl(lower)alkyl, cycloalkyl or cycloalkyl(lower)alkyl or R^8 and R^9 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom] or a group of formula OR^{11} [where R^{11} is lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl, aryl(lower)alkyl, heteroaryl or heteroaryl-(lower)alkyl].

5. A method as claimed in claim 4 wherein the compound of general formula (I) has the formula



where n , R , R^1 , R^2 , R^3 , R^4 and R^5 are as defined in claim 4.

6. A method as claimed in claim 4 wherein the compound of formula (I) is

N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenylpropanamide or its (S)-enantiomer or

2,3,4,5,6,7-hexahydro-1-[4-[1-[4-(2-methoxyphenyl)-piperazinyl]]-2-phenyl]butanoyl-1H-azepine or

(-)-(R)-2,3,4,5,6,7-hexahydro-1-[4-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl]butanoyl-1H-azepine or

N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclohexanecarboxamide.

7. A pharmaceutical composition for the treatment of cognitive disorders comprising a pharmaceutically acceptable carrier and a piperazine derivative of formula (I) as defined in claim 1 or a pharmaceutically acceptable acid addition salt thereof.

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/GB 93/02197

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K31/495 A61K31/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB,A,2 255 337 (WYETH) 4 November 1992 cited in the application see page 12 - page 14 ---	7
X	GB,A,2 230 781 (WYETH) 31 October 1990 cited in the application see page 14 - page 16 ---	7
X	GB,A,2 230 780 (WYETH & AMERICAN HOME PRODUCTS CORP.) 31 October 1990 cited in the application see page 36 - page 37 ---	7
X	GB,A,2 248 836 (WYETH) 22 April 1992 cited in the application see page 9 - page 10 ---	7
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 December 1993

Date of mailing of the international search report

10. 01. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Klaver, T

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/GB 93/02197

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>PHARMACOPSYCHIATRY vol. 23, no. SU 2 , 1990 pages 85 - 89 B. COSTALL ET AL. 'Biochemical models for cognition enhancers.' -----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No

PCT/GB 93/02197

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB-A-2255337	04-11-92	AU-A-	1524192	05-11-92
		EP-A-	0512755	11-11-92
		JP-A-	5170743	09-07-93

GB-A-2230781	31-10-90	AU-B-	619677	30-01-92
		AU-A-	5377890	25-10-90
		AU-B-	619678	30-01-92
		AU-A-	5377990	25-10-90
		EP-A-	0395312	31-10-90
		EP-A-	0395313	31-10-90
		GB-A, B	2230780	31-10-90
		GB-A, B	2255976	25-11-92
		JP-A-	3011059	18-01-91
		JP-A-	3020263	29-01-91
		US-A-	4921958	01-05-90
		US-A-	4988814	29-01-91

GB-A-2230780	31-10-90	AU-B-	619677	30-01-92
		AU-A-	5377890	25-10-90
		AU-B-	619678	30-01-92
		AU-A-	5377990	25-10-90
		EP-A-	0395312	31-10-90
		EP-A-	0395313	31-10-90
		GB-A, B	2230781	31-10-90
		GB-A, B	2255976	25-11-92
		JP-A-	3011059	18-01-91
		JP-A-	3020263	29-01-91
		US-A-	4921958	01-05-90
		US-A-	4988814	29-01-91
CA-A-	2015033	22-10-90		

GB-A-2248836	22-04-92	AU-B-	642044	07-10-93
		AU-A-	8592091	30-04-92
		EP-A-	0481744	22-04-92
		JP-A-	4282371	07-10-92
